| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC2706 | Indoluidin D | Novel inhibitor of dihydroorotate dehydrogenase (DHODH), promoting myeloid differentiation and inhibiting the proliferation of acute promyelocytic leukemia HL-60 cells, also suppressing cell growth in various other types of cancer cells |
|
| DCC2707 | Indotecan Hydrochloride | Topoisomerase I (Top1) inhibitor |
|
| DCC2708 | Indoxam | Novel sPLA2 inhibitor, suppressing murine endotoxic shock and LDL modification, blocking binding to the M-type receptor |
|
| DCC2709 | Indoxyl Sulfate | Metabolite of tryptophan, showing adverse effects on bones and the central nervous system, having been most frequently implicated as a contributor to renal disease progression and vascular disease |
|
| DCC2710 | Infraluciferin | NIR emitting firefly luciferin analogue |
|
| DCC2711 | Ingavirin | Novel inhibitor of the influenza virus reproduction, inhubiting the formation of the virus specific hemagglutinin |
|
| DCC2712 | inh-32 | Novel inhibitor of Ark1, the fission yeast member of the conserved Aurora kinase family |
|
| DCC2713 | Inhib1x | Novel dual inhibitor of MAPKAPK5 and MAPKAPK2 |
|
| DCC2714 | Inhibitor R1 | Novel Potent Inhibitor of Microbiome ß-Glucuronidases |
|
| DCC2715 | Inhibitor R3 | Novel Potent Inhibitor of Microbiome ß-Glucuronidases |
|
| DCC2716 | Inos-in-10 | Novel selective inhibitor of the iNOS, without affecting the eNOS isoform |
|
| DCC2717 | Inos-in-18 | Novel Potent and Selective Inducible Nitric Oxide Synthase (iNOS) Inhibitor (IC50 = 74 nM) with high BBB permeability (Pe = 19.1 × 10-6 cm/s) for Parkinson's Disease |
|
| DCC2718 | Inos-in-d27 | Novel Potent and Orally Active Inducible Nitric Oxide Synthase (iNOS) Dimerization Inhibitor with Efficacy in Rheumatoid Arthritis Mouse Model |
|
| DCC2719 | Inp1750 | Novel putative inhibitor of type III secretion (T3S) in the Gram-negative pathogen Yersinia pseudotuberculosis and Chlamydia trachomatis |
|
| DCC2720 | Ins015_037 | Novel potent inhibitor of DDR1 tyrosine kinase |
|
| DCC2721 | Ins3-54-a26 | Novel inhibitor of the DNA-binding domain (DBD) of STAT3, suppressing tumor growth, metastasis and STAT3 target gene expression in vivo |
|
| DCC2722 | Ins48823 | Activator of the P2Y6 receptor in bone, increasing survival of osteoclasts |
|
| DCC2723 | Int2-31 | Blocker of the interaction of FAK and IGF-1R; Antagonist of the phosphorylation of tumor AKT |
|
| DCC2724 | Intervenolin | Natural potent inhibitor of H. pylori DHODH, having greater efficacy for treatment of H. pylori infection |
|
| DCC2725 | Intoplicine | Inhibitor of both topoisomerase I and II via intercalating DNA helix |
|
| DCC2726 | Inuloxin A | Natural Activator of Programmed Cell Death, leading to membrane damage, mitochondria alteration, chromatin condensation, and ROS accumulation |
|
| DCC2727 | Inz-4 [1585213-98-4] | Novel Potent Fungal-Selective Inhibitor of Mitochondrial Cytochrome bc1 |
|
| DCC2728 | Iodiconazole | Novel antifungal agent, exhibiting broad spectrum and potent activity against 12 kinds of clinically pathogenic fungi |
|
| DCC2729 | Iodoclorgyline | Selective monoamine oxidase A inhibitor |
|
| DCC2730 | Ipcs-1 | Novel inhibitor of the plant inositol phosphorylceramide synthase ((IPCS), demonstrating herbicidal activity |
|
| DCC2731 | Iperoxo-bqca C6 | Muscarinic Acetylcholine Receptor Hybrid Ligand, possessing noticeable M2/M4 mAChR selectivity |
|
| DCC2732 | Ipi-269609 | Orally bioavailable inhibitor of Hedgehog signaling, inhibiting tumor initiation and metastasis in pancreatic cancer |
|
| DCC2733 | Ipomeamarone | Natural toxic furanoterpenoid found in mold-damaged sweet potatoes |
|
| DCC2734 | Ipomoeassin F | Natural inhibitor of the in vitro biogenesis of the SARS-CoV-2 spike protein and its host cell membrane receptor, binding Sec61α to Inhibit Protein Translocation |
|
| DCC2735 | Ipr-2025 | Novel inhibitor of glioblastoma multiforme (GBM), inhibiting cell viability of low-passage patient-derived GBM spheroids, blocking tube-formation of endothelial cells in Matrigel, showing no effect on primary hematopoietic CD34+ progenitor spheroids or as |
|
